Selective RET Inhibition in Metastatic RET-Mutant Medullary Thyroid Cancer and RET Fusion–Positive Differentiated Thyroid Cancer

Download these slides from a CCO Live Webinar to review the latest clinical data informing optimal treatment of metastatic RET-altered thyroid cancer.
Marcia Brose, MD, PhD, FASCO
Format: Microsoft PowerPoint (.ppt)
File Size: 1.97 MB
Released: March 16, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Downloadable slideset from a live meeting series for endocrinologists featuring best practices for biomarker testing and the latest evidence on targeted therapies for advanced thyroid cancer, from Clinical Care Options (CCO)

person default Maria E Cabanillas, MD person default Lori J. Wirth, MD Released: January 4, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Downloadable resource on the role of RET and NTRK aberrations in lung and thyroid cancer, including guidance on testing and review of the clinical data on RET and NTRK inhibitor therapy for these diseases, from Clinical Care Options (CCO)

Released: November 14, 2022

Video featuring pathology experts discussing molecular testing in lung and thyroid cancers, from Clinical Care Options (CCO)

Juan C. Hernandez-Prera, MD Jeremy P. Segal, MD, PhD Physicians: maximum of 0.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.5 Medical Knowledge MOC points ABPath MOC: maximum of 0.5 Lifelong Learning points Released: October 24, 2022 Expired: October 23, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings